Hopp til hovedinnhold

Premaligne forandringer i cervix

Sist revidert:
Sist revidert av:
Definisjon:
Forstadier til kreft på livmorhalsen, enten i plateepitel eller i kjertelepitel. Årsak er vedvarende infeksjon med et av de onkogene humane papillomavirusene.
Forekomst:
Det diagnostiseres årlig mer enn 8000 nye behandlingstrengende forstadier til livmorhalskreft i Norge.
Symptomer:
Tilstanden er vanligvis asymptomatisk.
Funn:
Vanligvis normale kliniske funn ved gynekologisk undersøkelse.
Diagnostikk:
Livmorhalsprøve til cytologisk analyse og HPV-test, kolposkopi, biopsi, cervikal abrasio.
Behandling:
Observasjon, konisering eller hysterektomi, bestemmes ut ifra histologi, alder og ev. barneønske.
  • Helsedirektoratet (2016). Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av gynekologisk kreft. Oslo; sist faglig oppdatert 18. januar 2023
  1. Helsedirektoratet (2016). Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av gynekologisk kreft [nettdokument]. Oslo: Helsedirektoratet (sist faglig oppdatert 18. januar 2023, lest 18. april 2023). www.helsedirektoratet.no  
  2. Kreftregisteret. Kvalitetsmanual for Livmorhalsprogrammet. Oslo, sist revidert nov 2022. Siden besøkt 18.04.2023 www.kreftregisteret.no  
  3. Kreftregisteret. Årsrapport 2021. Screeningaktivitet og resultater fra Livmorhalsprogrammet, Oslo, 2022. www.kreftregisteret.no  
  4. Dillner J, Nygård M, Munk C et al. Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs. Vaccine. 2018 Jun 18;36(26):3820-3829. Epub 2018 May 31. PMID: 29778519 PubMed  
  5. Gravitt PE. The known unknowns of HPV natural history. J Clin Invest. 2011 Dec;121(12):4593-9. Epub 2011 Dec 1. PMID: 22133884 PubMed  
  6. Eide LM, Baasland I. Celleprøvetaking fra cervix - er det så vanskelig?. Gynekologen 2014; 27 (2): 32-4. www.legeforeningen.no  
  7. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007; 370 (9590): 890. PMID: 17826171 PubMed  
  8. Kaderli R, Schnüriger B, Brügger LE. The impact of smoking on HPV infection and the development of anogenital warts. Int J Colorectal Dis 2014. pmid:24935346 PubMed  
  9. Jensen KE, Thomsen LT, Schmiedel S. Chlamydia trachomatis and risk of cervical intraepithelial neoplasia grade 3 or worse in women with persistent human papillomavirus infection: a cohort study. Sex Transm Infect 2014. PMID: 24728044 PubMed  
  10. World Health Organization. Comprehensive cervical cancer control. A guide to essential practice. Second edition. Geneva: WHO; 2014. www.who.int  
  11. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006; 354: 2645-54. PMID: 16790697 PubMed  
  12. Trottier H, Mahmud S, Costa MC, et al. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2006; 15: 1274-80. PMID: 16835323 PubMed  
  13. Kreftregisteret. Livmorhalsprogrammet. HPV i primærscreening. Sist oppdatert 12.03.2018. Siden besøkt 02.08.2018. www.kreftregisteret.no  
  14. Sørbye SW, Arbyn M, Fismen S, et al. HPV E6/E7 mRNA testing is more specific than cytology in post-colposcopy follow-up of women with negative cervical biopsy. PLoS One 2011; 6(10): e26022. pmid:21998748 PubMed  
  15. Ronco G, Dillner J, Elfstrom KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2013 Nov 1.Lancet. PubMed PMID: 24192252. PubMed  
  16. Ogilvie GS, van Niekerk D, Krajden M, et al. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months The HPV FOCAL Randomized Clinical Trial. JAMA 2018; 320: 43-52. pmid:29971397 PubMed  
  17. Koliopoulos G, Nyaga VN, Santesso N et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev 2017; 8: CD008587. DOI: 10.1002/14651858.CD008587.pub2. The Cochrane Library  
  18. Arbyn M, Smith SB, Temin S et al. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ 2018. PMID: 30518635 PubMed  
  19. Polman NJ, Ebisch RMF, Heideman DAM et al. Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial. Lancet Oncol 2019; 20: 229-38. pmid:30658933 PubMed  
  20. Leinonen MK, Schee K, Jonassen CM et al. Safety and acceptability of human papillomavirus testing of self-collected specimens: A methodologic study of the impact of collection devices and HPV assays on sensitivity for cervical cancer and high-grade lesions. J Clin Virol 2018; 99: 22-30. pmid:29289814 PubMed  
  21. Aasbø G, Tropè A, Nygård M et al. HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: a pragmatic randomised controlled trial. Br J Cancer. 2022 Nov;127(10):1816-1826. Epub 2022 Aug 23. PMID: 35995936 PubMed  
  22. Skjeldestad FE, Hagen B, Hagmar B, Iversen O-E, Juvkam KH, Steen R, Thoresen S, Hareide B. Er cervixcytologisk undersøkelse av unge kvinner mer til skade enn til gagn?. Tidsskr Nor Lægeforen 2007; 127: 1782-5. PubMed  
  23. Helsedirektoratet. Nasjonalt handlingsprogram med retninglinjer for gynekologisk kreft. Helsedirektoratet. Oslo, mai 2020. www.helsedirektoratet.no  
  24. Baasland I, Munk AC, Ernø LE et al. Premaligne og maligne forandringer i cervix i graviditet. Veileder i fødselshjelp. Norsk gynekologisk forening. Oslo, 2020. Siden besøkt 18.04.2023 www.legeforeningen.no  
  25. Vaksinasjonsveilederen: HPV-vaksine - veileder for helsepersonell. Folkehelseinstituttet. Oppdatert: 30.09.2022. Siden besøkt 18.04.2023 www.fhi.no  
  26. Sand FL, Kjaer SK, Frederiksen K, Dehlendorff C. Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status. Int J Cancer. 2020 Aug 1;147(3):641-647. PMID: 31648368.
  27. Tainio K, Athanasiou A, Tikkinen KAO et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. BMJ 2018; 360 :k499. PMID: 29487049 PubMed  
  28. Koeneman MM, van Lint FHM, van Kuijk SMJ et al. A prediction model for spontaneous regression of cervical intraepithelial neoplasia grade 2, based on simple clinical parameters. Hum Pathol 2017; 59: 62-9. pmid:27697590 PubMed  
  29. Bjørge T, Skare GB, Bjørge L, Tropé A, Lönnberg S. Adverse Pregnancy Outcomes After Treatment for Cervical Intraepithelial Neoplasia. Obstet Gynecol. 2016;128(6):1265-1273. PMID: 27824756 PubMed  
  30. Kyrgiou M, Athanasiou A, Paraskevaidi M, et al. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ. 2016;354:i3633. Published 2016 Jul 28. PMID: 27469988 PubMed  
  31. Kyrgiou M, Athanasiou A, Kalliala IEJ et al. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. Cochrane Database of Systematic Reviews 2017, Issue 11. Art. No.: CD012847. DOI: 10.1002/14651858.CD012847. The Cochrane Library  
  32. Danckert B, Ferlay J, Engholm G et al. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Data version: 9.2 - 23.06.2022. Hentet 18.04.2023 www.ancr.nu  
  • Ameli Tropé, overlege dr. med, Kreftregisteret
  • Silje Folven Barlindhaug, spesialist i allmennmedisin, redaktør NEL

Tidligere fagmedarbeidere

  • Finn Egil Skjeldestad, lege og professor, Institutt for samfunnsmedisinske fag UiT Norges arktiske universitet, Tromsø
  • Sveinung Sørbye, overlege PhD, avdeling for klinisk patologi, Universitetssykehuset i Nord-Norge, Tromsø